Journal article
The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft
MJ Rees, P Mollee, JY Ng, A Murton, JF Gonsalves, A Panigrahi, H Beer, J Loh, P Nguyen, S Hunt, H Jina, R Wayte, G Sutrave, J Tan, C Abeyakoon, A Chee, B Augustson, A Kalro, C Lee, S Agrawal Show all
Bone Marrow Transplantation | SPRINGERNATURE | Published : 2021
Abstract
G-CSF only mobilisation has been shown to enhance immune reconstitution early post-transplant, but its impact on survival remains uncertain. We undertook a retrospective review of 12 transplant centres to examine overall survival (OS) and time to next treatment (TTNT) following melphalan autograft according to mobilisation method (G-CSF only vs. G-CSF and cyclophosphamide [CY]) in myeloma patients uniformly treated with bortezomib, cyclophosphamide and dexamethasone induction. Six centres had a policy to use G-CSF alone and six to use G-CSF + CY. Patients failing G-CSF only mobilisation were excluded. 601 patients were included: 328: G-CSF + CY, 273: G-CSF only. Mobilisation arms were compar..
View full abstract